GENFIT Email Format
Biotechnology ResearchHauts-de-france, France201-500 Employees
GENFIT is a biopharmaceutical company focused on rare and life-threatening liver diseases with high unmet medical needs. With over two decades of liver disease research, it advances assets from early development to late-stage and pre-commercial programs, including a 52-week readout from the ELATIVE Phase 3 trial in primary biliary cholangitis. Its pipeline covers multiple ACLF programs at clinical and preclinical stages, a Phase 2 program for cholangiocarcinoma, preclinical efforts for urea cycle disorders and organic acidemias, and a diagnostic franchise for MASH/NASH and ammonia.